<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5707975 - Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer"><meta name="DC.contributor" content="Marc Karel Jozef FranÃ§ois" scheme="inventor"><meta name="DC.contributor" content="Willy Maria Albert Carlo Dries" scheme="inventor"><meta name="DC.contributor" content="Janssen Pharmaceutica, N.V." scheme="assignee"><meta name="DC.date" content="1994-9-22" scheme="dateSubmitted"><meta name="DC.description" content="The present invention concerns a formulation for oral administration comprising an antifungal, a sufficient amount of a cyclodextrin or a derivative thereof, an aqueous acidic medium as bulk liquid carrier and an alcoholic co-solvent Addition of one or more pharmaceutically acceptable sweeteners and one or more pharmaceutically acceptable flavors thereto yields palatable oral formulations. A process of preparing such formulations and pharmaceutical dosage forms comprising said formulations."><meta name="DC.date" content="1998-1-13" scheme="issued"><meta name="DC.relation" content="US:3459731" scheme="references"><meta name="DC.relation" content="US:4267179" scheme="references"><meta name="DC.relation" content="US:4383992" scheme="references"><meta name="DC.relation" content="US:4659696" scheme="references"><meta name="DC.relation" content="US:4764604" scheme="references"><meta name="DC.relation" content="US:4863737" scheme="references"><meta name="DC.relation" content="US:4870060" scheme="references"><meta name="DC.relation" content="US:4883785" scheme="references"><meta name="DC.relation" content="US:4916134" scheme="references"><meta name="DC.relation" content="US:4983586" scheme="references"><meta name="DC.relation" content="US:4990337" scheme="references"><meta name="DC.relation" content="WO:1993019061:A1" scheme="references"><meta name="citation_reference" content="Hostetler et al., &quot;Effect of Cyclodextrin on the Pharmacology of Antifungal Oral Azoles&quot;, Antimicrobial Agents And Chemotherapy, Feb. 1992, pp. 477-480."><meta name="citation_reference" content="Hostetler et al., Effect of Cyclodextrin on the Pharmacology of Antifungal Oral Azoles , Antimicrobial Agents And Chemotherapy , Feb. 1992, pp. 477 480."><meta name="citation_reference" content="Pitha et al., &quot;Preparation of drug:hydroxypropylcyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as co-solubilizers&quot;, International Journal of Pharmaceutics, 80 (1992) 253-258."><meta name="citation_reference" content="Pitha et al., Preparation of drug:hydroxypropylcyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as co solubilizers , International Journal of Pharmaceutics , 80 (1992) 253 258."><meta name="citation_patent_number" content="US:5707975"><meta name="citation_patent_application_number" content="US:08/604,950"><link rel="canonical" href="http://www.google.com/patents/US5707975"/><meta property="og:url" content="http://www.google.com/patents/US5707975"/><meta name="title" content="Patent US5707975 - Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer"/><meta name="description" content="The present invention concerns a formulation for oral administration comprising an antifungal, a sufficient amount of a cyclodextrin or a derivative thereof, an aqueous acidic medium as bulk liquid carrier and an alcoholic co-solvent Addition of one or more pharmaceutically acceptable sweeteners and one or more pharmaceutically acceptable flavors thereto yields palatable oral formulations. A process of preparing such formulations and pharmaceutical dosage forms comprising said formulations."/><meta property="og:title" content="Patent US5707975 - Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("ECXuU8jDMbCysQS2q4D4BA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("POL"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("ECXuU8jDMbCysQS2q4D4BA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("POL"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5707975?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5707975"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=srhEBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5707975&amp;usg=AFQjCNEAsh2CcBBAqe_LtIVIrlRZR8Fz9g" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5707975.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5707975.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5707975" style="display:none"><span itemprop="description">The present invention concerns a formulation for oral administration comprising an antifungal, a sufficient amount of a cyclodextrin or a derivative thereof, an aqueous acidic medium as bulk liquid carrier and an alcoholic co-solvent Addition of one or more pharmaceutically acceptable sweeteners and...</span><span itemprop="url">http://www.google.com/patents/US5707975?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5707975 - Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5707975 - Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer" title="Patent US5707975 - Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5707975 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/604,950</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/EP1994/003169</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jan 13, 1998</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Sep 22, 1994</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Sep 30, 1993</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2170622A1">CA2170622A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2170622C">CA2170622C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1086579C">CN1086579C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1136776A">CN1136776A</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69429359D1">DE69429359D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69429359T2">DE69429359T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0721337A1">EP0721337A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0721337B1">EP0721337B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1995008993A1">WO1995008993A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08604950, </span><span class="patent-bibdata-value">604950, </span><span class="patent-bibdata-value">PCT/1994/3169, </span><span class="patent-bibdata-value">PCT/EP/1994/003169, </span><span class="patent-bibdata-value">PCT/EP/1994/03169, </span><span class="patent-bibdata-value">PCT/EP/94/003169, </span><span class="patent-bibdata-value">PCT/EP/94/03169, </span><span class="patent-bibdata-value">PCT/EP1994/003169, </span><span class="patent-bibdata-value">PCT/EP1994/03169, </span><span class="patent-bibdata-value">PCT/EP1994003169, </span><span class="patent-bibdata-value">PCT/EP199403169, </span><span class="patent-bibdata-value">PCT/EP94/003169, </span><span class="patent-bibdata-value">PCT/EP94/03169, </span><span class="patent-bibdata-value">PCT/EP94003169, </span><span class="patent-bibdata-value">PCT/EP9403169, </span><span class="patent-bibdata-value">US 5707975 A, </span><span class="patent-bibdata-value">US 5707975A, </span><span class="patent-bibdata-value">US-A-5707975, </span><span class="patent-bibdata-value">US5707975 A, </span><span class="patent-bibdata-value">US5707975A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Marc+Karel+Jozef+Fran%C3%A7ois%22">Marc Karel Jozef FranÃ§ois</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Willy+Maria+Albert+Carlo+Dries%22">Willy Maria Albert Carlo Dries</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Janssen+Pharmaceutica,+N.V.%22">Janssen Pharmaceutica, N.V.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5707975.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5707975.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5707975.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (12),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (4),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (18),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (21),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (7)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5707975&usg=AFQjCNE7f7HsRbuj8e1118REDGOCYVG6hQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5707975&usg=AFQjCNFTAlZ7c_uCJXGKpmrYOK7R72peyg">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5707975A%26KC%3DA%26FT%3DD&usg=AFQjCNFb3vxWOcIRd5lnRyed99Ozpo0XRA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT128959052" lang="EN" load-source="ifi">Itraconazole or saperconazole, hydroxypropyl-b-cyclodextrin solubilizer</invention-title></span><br><span class="patent-number">US 5707975 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37717555" lang="EN" load-source="patent-office"> <div class="abstract">The present invention concerns a formulation for oral administration comprising an antifungal, a sufficient amount of a cyclodextrin or a derivative thereof, an aqueous acidic medium as bulk liquid carrier and an alcoholic co-solvent Addition of one or more pharmaceutically acceptable sweeteners and one or more pharmaceutically acceptable flavors thereto yields palatable oral formulations. A process of preparing such formulations and pharmaceutical dosage forms comprising said formulations.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(6)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5707975-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5707975-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5707975-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5707975-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5707975-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5707975-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5707975-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5707975-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5707975-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5707975-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5707975-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5707975-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(7)</span></span></div><div class="patent-text"><div mxw-id="PCLM59460187" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>We claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A formulation for oral administration comprising:<div class="claim-text">(a) itraconazole or saperconazole;</div> <div class="claim-text">(b) a sufficient amount of a hydroxypropyl-Î²-cyclodextrin having an M.S. in the range of 0.3 to 3 and containing less than 5% unsubstituted Î²-cyclodextrin, to act as a solubilizer for the itraconazole or saperconazole;</div> <div class="claim-text">(c) an aqueous acidic medium as bulk liquid carrier;</div> <div class="claim-text">(d) from about 1% (v/v) to about 20% (v/v) of an alcoholic co-solvent selected from the group consisting of ethanol, propylene glycol and glycerol;</div> <div class="claim-text">(e) one or more pharmaceutically acceptable intense sweeteners plus one or more bulk sweeteners; and</div> <div class="claim-text">(f) one or more pharmaceutically acceptable flavors.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. A formulation according to claim 1 wherein the cyclodextrin is hydroxypropyl-Î²-cyclodextrin having an M.S. in the range of 0.35 to 0.50 and containing less than 1.5% unsubstituted Î²-cyclodextrin.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. A formulation according to claim 2 wherein the alcoholic co-solvent is propylene glycol.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. A formulation according to claim 3 having a pH of 2.0Â±0.1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. A formulation according to claim 4 wherein the intense sweetener is selected from the group consisting of saccharin, sodium or calcium saccharin and the bulk sweetener is selected from the group consisting of sorbitol, mannitol, fructose, sucrose, maltose, glucose, caramel or honey.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A formulation according to claim 1 comprising by weight or by volume based on the total volume of the formulation:<div class="claim-text">(a) 4% (w/v) itraconazole;</div> <div class="claim-text">(b) 60% (w/v) hydroxypropyl-Î²-cyclodextrin;</div> <div class="claim-text">(c) 10% (v/v) propylene glycol;</div> <div class="claim-text">(d) acid and base to adjust the pH of the composition within the range of 2.0Â±0.1;</div> <div class="claim-text">(e) 0.08% (w/v) sodium saccharin;</div> <div class="claim-text">(f) up to 1% (w/v) of one or more flavours; and</div> <div class="claim-text">(g) water.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. A formulation according to claim 1 comprising by weight or by volume based on the total volume of the formulation:<div class="claim-text">(a) 1% (w/v) itraconazole or saperconazole;</div> <div class="claim-text">(b) 40% (w/v) hydroxypropyl-Î²-cyclodextrin;</div> <div class="claim-text">(c) 10% (v/v) propyleneglycol;</div> <div class="claim-text">(d) acid or base to adjust the pH of the composition within the range of 2.0Â±0.1;</div> <div class="claim-text">(e) 0.06% (w/v) sodium saccharin;</div> <div class="claim-text">(f) 19% (v/v) sorbitol (70%) non-crystallizing solution;</div> <div class="claim-text">(g) up to 1% (w/v) of one or more flavours;</div> <div class="claim-text">(h) 0.02% (w/v) of a carmel sweetener; and</div> <div class="claim-text">(i) water.</div> </div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67065646" lang="EN" load-source="patent-office" class="description">
    <heading>CROSS-REFERENCE TO RELATED APPLICATIONS</heading> <p>This application is based upon PCT application Ser. No. PCT/EP 94/03169, filed Sep. 22, 1994, which claims priority from U.S. patent application Ser. No. 08/129,504, filed on Sep. 30, 1993 now abandoned.</p>
    <heading>CROSS-REFERENCE TO RELATED APPLICATIONS</heading> <p>This application is based upon PCT application Ser. No. PCT/EP 94/03169, filed Sep. 22, 1994, which claims priority from U.S. patent application Ser. No. 08/129,504, filed on Sep. 30, 1993 now abandoned.</p>
    <p>The present invention is concerned with novel compositions of antifungal agents which have low solubility in aqueous media, a process for preparing said compositions and pharmaceutical dosage forms for oral administration comprising said novel compositions.</p>
    <p>The development of efficacious pharmaceutical compositions of azole antifungals such as for example, itraconazole and saperconazole, is hampered considerably by the fact that said antifungals are only very sparingly soluble in water. The solubility and bioavailability of said compounds can be increased by complexation with cyclodextrins or derivatives thereof as described in WO 85/02767 and U.S. Pat. No. 4,764,604. Alternatively, strongly acidic formulations (pHâ¦1.5) of itraconazole and saperconazole can be formed in which the active ingredients are partially dissolved. Obviously such strongly acidic formulations are useless for oral administration. Aqueous formulations comprising a co-solvent such as PEG 400 completely dissolve itraconazole at pH 2.3-2.5. However, these acidic formulations have problems with regard to ease-of-preparation, acceptability, palatability and especially bioavailability: upon administration said formulations can precipitate irreversibly, e.g. in the stomach. Acidic formulations comprising cyclodextrin or a derivative thereof might appear an obvious alternative, but the mere combinations prove to suffer from a number of similar problems, in particular difficulty-of-preparation, lack of stability (shelf life) and palatability, and unreliable absorption. In short, there still exists an important demand for easily prepared formulations of antifungal agents with good bioavailability and acceptable organoleptic properties for oral administration.</p>
    <p>The present invention relates to formulations for oral administration which comprise an antifungal, e.g. itraconazole or saperconazole, as active ingredient, a sufficient mount of a cyclodextrin or a derivative thereof as a solubilizer, an aqueous acidic medium as bulk liquid carrier and an alcoholic co-solvent that greatly simplifies the preparation of the composition. Preferred formulations are rendered more palatable by adding one or more pharmaceutically acceptable sweeteners, and one or more pharmaceutically acceptable flavours.</p>
    <p>A low-dosage formulation according to the present invention is suitable for treating patients suffering from fungal infections, particularly for treating AIDS patients with oral candidiasis infections. The need for reliable formulations of itraconazole (and saperconazole) in this indication is especially high because of resistance to fluconazole developing in Candida strains. Generally, 400 mg/day represents the minimum dose required to obtain meaningful plasm levels. Suitable oral formulations typically comprise from about 0.5% to about 1.5% (w/v), preferably about 1% (w/v) of the active ingredient.</p>
    <p>A high-dosage formulation according to the present invention is suitable for treating patients suffering from systemic fungal infections. Suitable oral formulations for combatting systemic fungal infections typically comprise from about 3% to about 5%, preferably about 4% (w/v) of the active ingredient.</p>
    <p>The formulations of the present invention are also suitable for the treatment of fungal infections in non-human animals, in particular for the treatment of dermatophytoses.</p>
    <p>Itraconazole or (Â±)-cis-4- 4- 4- 4-  2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl!methoxy!phenyl!-1-piperazinyl!phenyl!-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one, is a broadspectrum antifungal compound developed for oral, parenteral and topical use and is disclosed in U.S. Pat. No. 4,267,179. Its difluoro analog, saperconazole or (Â±)-cis-4- 4- 4- 4-  2-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl!methoxy!phenyl!-1-piperazinyl!-phenyl!-2,4-dihydro-2-(1-methoxypropyl)-3H-1,2,4-triazol-3-one, has improved activity against Aspergillus spp. and is disclosed in U.S. Pat. No. 4,916,134.</p>
    <p>Appropriate cyclodextrin derivatives are Î±-, Î²-, Î³-cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with C<sub>1-6</sub> alkyl, particularly methyl, ethyl or isopropyl; hydroxyC<sub>1-6</sub> alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxybutyl; carboxyC<sub>1-6</sub> alkyl, particularly carboxymethyl or carboxyethyl; C<sub>1-6</sub> alkylcarbonyl, particularly acetyl; C<sub>1-6</sub> alkyloxycarbonylC<sub>1-6</sub> alkyl or carboxyC<sub>1-6</sub> alkyloxyC<sub>1-6</sub> alkyl, particularly carboxymethoxypropyl or carboxyethoxypropyl; C<sub>1-6</sub> alkylcarbonyloxyC<sub>1-6</sub> alkyl, particularly 2-acetyloxypropyl. Especially noteworthy as complexants and/or solubilizers are Î²-CD, 2,6-dimethyl-Î²-CD, 2-hydroxyethyl-Î²-CD, 2-hydroxyethyl-Î³-CD, 2-hydroxypropyl-Î³-CD and (2-carboxymethoxy)propyl-Î²-CD, and in particular 2-hydroxypropyl-Î²-CD.</p>
    <p>The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxypropyl and hydroxyethyl.</p>
    <p>The average molar substitution (M.S.) is used as a measure of the average number of moles of alkoxy units per mole of anhydroglucose. In the cyclodextrin derivatives for use in the compositions according to the present invention the M.S. is in the range of 0.125 to 10, in particular of 0.3 to 3, or from 0.3 to 1.5. Preferably the M.S. ranges from about 0.3 to about 0.8, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. M.S. values determined by NMR of IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.</p>
    <p>The average substitution degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit. In the cyclodextrin derivatives for use in the compositions according to the present invention the D.S. is in the range of 0.125 to 3, in particular of 0.2 to 2 or from 0.2 to 1.5. Preferably the D.S. ranges from about 0.2 to about 0.7, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. D.S. values determined by NMR of IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.</p>
    <p>More particular Î²- and Î³-cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention are partially substituted cyclodextrin derivatives wherein the average degree of alkylation at hydroxyl groups of different positions of the anhydroglucose units is about 0% to 20% for the 3 position, 2% to 70% for the 2 position and about 5% to 90% for the 6 position. Preferably the amount of unsubstituted Î²- or Î³-cyclodextrin is less than 5% of the total cyclodextrin content and in particular is less than 1.5%. Another particularly interesting cyclodexuin derivative is randomly methylated Î²-cyclodextrin.</p>
    <p>Most preferred cyclodextrin derivatives for use in the present invention are those partially substituted Î²-cyclodextrin ethers or mixed ethers having hydroxypropyl, hydroxyethyl and in particular 2-hydroxypropyl and/or 2-(1-hydroxypropyl) substituents.</p>
    <p>The most preferred cyclodextrin derivative for use in the compositions of the present invention is hydroxypropyl-Î²-cyclodextrin having a M.S. in the range of from 0.35 to 0.50 and containing less than 1.5% unsubstituted Î²-cyclodextrin. M.S. values determined by NMR or IR preferably range from 0.55 to 0.75.</p>
    <p>Substituted cyclodextrins can be prepared according to procedures described in U.S. Pat. No. 3,459,731, EP-A-0,149,197, EP-A-0,197,571, U.S. Pat. No. 4,535,152, WO-90/12035 and GB-2,189,245. Other references describing cyclodextrins for use in the compositions according to the present invention, and which provide a guide for the preparation, purification and analysis of cyclodextrins include the following: "Cyclodextrin Technology" by Jozsef Szejtli, Kluwer Academic Publishers (1988) in the chapter Cyclodextrins in Pharmaceuticals; "Cyclodextrin Chemistry" by M. L. Bender et at., Springer-Verlag, Berlin (1978); "Advances in Carbohydrate Chemistry", Vol. 12 Ed. by M. L. Wolfrom, Academic Press, New York (157) in the chapter The Schardinger Dextrins by Dexter French at p. 189-260; "Cyclodextrins and their Inclusions Complexes" by J. Szejtli, Akademiai Kiado, Budapest, Hungary (1982); I. Tabushi in Acc. Chem. Research, 1982, 15, p. 66-72; W. Sanger, Angewandte Chemic, 92, p. 343-361 (1981); A. P. Croft and R. A. Bartsch in Tetrahedron, 39, p. 1417-1474 (1983); Irie et al. Pharmaceutical Research, 5, p. 713-716, (1988); Pitha et al. Int. J. Pharm. 29, 73, (1986); DE 3,118,218; DE-3,317,064; EP-A-94,157; U.S. Pat No. 4,659,696; and U.S. Pat. No. 4,383,992. The low-dosage oral formulations according to the present invention typically comprise from about 20% to about 60% (w/v), preferably about 40% (w/v) of the cyclodextrin. The high-dosage formulations typically comprise from about 50% to about 80% (w/v), preferably about 60% (w/v) of the cyclodextrin derivative.</p>
    <p>In order to increase the rate of dissolution of the poorly soluble antifungal during the manufacturing process, an alcoholic co-solvent is employed in the formulations according to the present invention. For this purpose, preference is given to those alcoholic co-solvents that have good dissolving power for itraconazole and/or saperconazole, in particular ethanol, propylene glycol and glycerol, especially propylene glycol. Without the alcoholic co-solvent, the dissolution of itraconazole or saperconazole in an aqueous acidic cyclodextrin medium is very slow, requiring a viscous suspension to be stirred for a prohibitively long time until complete dissolution is obtained. Addition of the alcoholic co-solvent, in the range of about 1% (v/v) to about 20% (v/v), preferably about 10% (v/v), increases the dissolution rate of the antifungal agent in an aqueous acidic cyclodextrin medium by a factor of at least 5 (when used at 10% (v/v)) and thus considerably shortens and simplifies the production process.</p>
    <p>As a bulk liquid carrier there is used an acidic aqueous medium. Preferably the acidity of said carrier derives from a strong, pharmaceutically acceptable acid such as hydrochloric acid. The bioavailability of the antifungal agent and the organoleptic properties of the oral formulations are affected contrariwise by the acidity. An optimum effect can be obtained at pH 2.0Â±0.1: that is, at this pH value, a sufficiently stable and bioavailable antifungal formulation is obtainable, the organoleptic properties of which can be rendered acceptable.</p>
    <p>Not surprisingly, the ingredients thus far described yield a fairly strong-tasting potion when mixed with one another. Besides the acid taste due to the low pH, a bitter taste originating from the active ingredient, and possibly from the co-solvent (e.g. in the case of propylene glycol), is also present. Optimum taste masking can be obtained by the use of two types of adjuvants, namely pharmaceutically acceptable sweeteners and flavours. Sweeteners are the more important additives in the low-dosage formulations, whereas the flavours are more important in the high-dosage formulations.</p>
    <p>The pharmaceutically acceptable sweeteners comprise preferably at least one intense sweetener such as saccharin, sodium or calcium saccharin, aspartame, acesulfame potassium, sodium cyclamate, alitame, a dihydrochalcone sweetener, monellin, stevioside or sucralose (4,1',6'-trichloro-4,1',6'-trideoxygalactosucrose), preferably saccharin, sodium or calcium saccharin, and optionally a bulk sweetener such as sorbitol, mannitol, fructose, sucrose, maltose, isomalt, glucose, hydrogenated glucose syrup, xylitol, caramel or honey.</p>
    <p>The intense sweetener is conveniently employed in low concentrations. For example, in the case of sodium saccharin, the concentration may range from 0.04% to 0.1% (w/v) based on the total volume of the final formulation, and preferably is about 0.06% in the low-dosage formulations and about 0.08% in the high-dosage ones. The bulk sweetener can effectively be used in larger quantities ranging from about 10% to about 35%, preferably from about 10% to 15% (w/v). In the high-dosage formulations the cyclodextrin derivative behaves as a bulk sweetener and none of the aforementioned bulk sweeteners needs to be added.</p>
    <p>The pharmaceutically acceptable flavours which can mask the bitter tasting ingredients in the low-dosage formulations are preferably fruit flavours such as cherry, raspberry, black currant or strawberry flavour. A combination of two cherry flavours was found to yield very good results in an itraconazole formulation both as regards physico-chemical stability as well as regards organoleptic acceptability. In the high-dosage formulations stronger flavours are required such as Caramel Chocolate flavour, Mint Cool flavour, Fantasy flavour and the like pharmaceutically acceptable strong flavours. Each flavour may be present in the final composition in a concentration ranging from 0.05% to 1% (w/v). Combinations of said strong flavours are advantageously used. Preferably a flavour is used that does not undergo any change or loss of taste and colour under the acidic conditions of the formulation.</p>
    <p>A preferred high-dosage formulation according to the present invention comprises by weight or by volume based on the total volume of the formulation:</p>
    <p>(a) 4% (w/v) itraconazole;</p>
    <p>(b) 60% (w/v) hydroxypropyl-Î²-cyclodextrin;</p>
    <p>(c) 10% (v/v) propylene glycol;</p>
    <p>(d) acid and base to adjust the pH of the composition within the range of 2.0Â±0.1;</p>
    <p>(e) 0.08% (w/v) sodium saccharin;</p>
    <p>(f) up to 1% (w/v) of one or more strong flavours; and</p>
    <p>(g) water.</p>
    <p>The preparation of the formulations according to the present invention will hereafter be described with regard to a preferred low-dosage formulation having the following composition (% are by weight or by volume based on the total volume of the formulation):</p>
    <p>(a) 1% (w/v) itraconazole;</p>
    <p>(b) 40% (w/v) hydroxypropyl-Î²-cyclodextrin;</p>
    <p>(c) 10% (v/v) propylene glycol;</p>
    <p>(d) acid and base to adjust the pH of the composition within the range of 2.0Â±0.1;</p>
    <p>(e) 0.06% (w/v) sodium saccharin;</p>
    <p>(f) 19% (v/v) sorbitol (70%) non-crystallizing solution;</p>
    <p>(g) up to 1% (w/v) of one or more cherry flavours; and</p>
    <p>(h) water.</p>
    <p>Optionally, the above preferred low-dosage formulation further comprises up to 0.1%, in particular 0.02% caramel sweetener.</p>
    <p>Similar formulations can be prepared with saperconazole, though other flavours may be preferred then.</p>
    <p>Said process of preparation comprises the steps of</p>
    <p>(a) dissolving the active ingredient in the alcoholic co-solvent and acid;</p>
    <p>(b) dissolving the cyclodextrin in water and adding thereto the solution prepared in</p>
    <p>(a) while stirring until homogenous;</p>
    <p>(c) adding the sweetener(s) and the flavour(s);</p>
    <p>(d) adjusting the acidity to pH 2.0Â±0.1 and</p>
    <p>(e) diluting the formulation to the desired end-volume.</p>
    <p>In particular, for preparing 1 liter of the aforementioned preferred formulation 100 ml of propylene glycol is treated with 3.76 ml concentrated HCl, stirred and slightly heated. 10 g itraconazole is added and stirring is continued until homogeneous.</p>
    <p>In a separate vessel, 400 g hydroxypropyl-Î²-cyclodextrin is dissolved in 400 ml distilled water. The solution of the active ingredient is added slowly to the cyclodextrin solution while stirring. The sorbitol solution (190 ml) is added and stirred till homogeneous. The sodium saccharin (0.6 g) is dissolved in 50 ml distilled water and added to the mixture. The flavours are added and the pH of the mixture (about 1.7) is adjusted with a 10N NaOH solution to pH 2.0Â±0.1. The resulting solution is diluted with distilled water to an end volume of 1 liter. A pharmaceutical dosage form is obtained by filtering the previous solution and filling it into suitable containers. e.g. in 100 ml glass bottles with a screw cap. The pharmaceutical dosage form advantageously comprises a minimal volume of air above the solution, preferably an inert gas such as nitrogen. Besides the exclusion of air (oxygen), storage at temperatures below 25Â° C. also beneficially affects the maximum shelf life of the formulation for oral administration.</p>
    <p>In case a more simple formulation lacking the flavour(s) and/or sweetener(s) is envisaged, step (c) is omitted partially or completely from the process of preparation.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3459731">US3459731</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 16, 1966</td><td class="patent-data-table-td patent-date-value">Aug 5, 1969</td><td class="patent-data-table-td ">Corn Products Co</td><td class="patent-data-table-td ">Cyclodextrin polyethers and their production</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4267179">US4267179</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 14, 1979</td><td class="patent-data-table-td patent-date-value">May 12, 1981</td><td class="patent-data-table-td ">Janssen Pharmaceutica, N.V.</td><td class="patent-data-table-td ">As fungicides and bactericides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4383992">US4383992</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 8, 1982</td><td class="patent-data-table-td patent-date-value">May 17, 1983</td><td class="patent-data-table-td ">Lipari John M</td><td class="patent-data-table-td ">Inclusion compounds with beta-cyclodextrin, antiinflammatory</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4659696">US4659696</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 22, 1983</td><td class="patent-data-table-td patent-date-value">Apr 21, 1987</td><td class="patent-data-table-td ">Takeda Chemical Industries, Ltd.</td><td class="patent-data-table-td ">Pharmaceutical composition and its nasal or vaginal use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4764604">US4764604</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 27, 1986</td><td class="patent-data-table-td patent-date-value">Aug 16, 1988</td><td class="patent-data-table-td ">Janssen Pharmaceutica N.V.</td><td class="patent-data-table-td ">Derivatives of gamma-cyclodextrin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4863737">US4863737</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 8, 1987</td><td class="patent-data-table-td patent-date-value">Sep 5, 1989</td><td class="patent-data-table-td ">University Of Utah</td><td class="patent-data-table-td ">Transmucosal delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4870060">US4870060</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 25, 1988</td><td class="patent-data-table-td patent-date-value">Sep 26, 1989</td><td class="patent-data-table-td ">Janssen Pharmaceutica</td><td class="patent-data-table-td ">Derivatives of Î³-cylodextrin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4883785">US4883785</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 27, 1984</td><td class="patent-data-table-td patent-date-value">Nov 28, 1989</td><td class="patent-data-table-td ">Chow Wing Sun</td><td class="patent-data-table-td ">Complex of anti-fungal agent and cyclodextrin and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4916134">US4916134</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 7, 1989</td><td class="patent-data-table-td patent-date-value">Apr 10, 1990</td><td class="patent-data-table-td ">Janssen Pharmacuetica N.V.</td><td class="patent-data-table-td ">Fungicides, bactericides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4983586">US4983586</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 29, 1988</td><td class="patent-data-table-td patent-date-value">Jan 8, 1991</td><td class="patent-data-table-td ">University Of Florida</td><td class="patent-data-table-td ">Pharmaceutical formulations for parenteral use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4990337">US4990337</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 12, 1990</td><td class="patent-data-table-td patent-date-value">Feb 5, 1991</td><td class="patent-data-table-td ">Sankyo Company Limited</td><td class="patent-data-table-td ">Increased solubility and dispersibility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1993019061A1?cl=en">WO1993019061A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 10, 1993</td><td class="patent-data-table-td patent-date-value">Sep 30, 1993</td><td class="patent-data-table-td ">Janssen Pharmaceutica Nv</td><td class="patent-data-table-td ">Itraconazole and saperconazole stereoisomers</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hostetler et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+Cyclodextrin+on+the+Pharmacology+of+Antifungal+Oral+Azoles"'>Effect of Cyclodextrin on the Pharmacology of Antifungal Oral Azoles</a>", Antimicrobial Agents And Chemotherapy, Feb. 1992, pp. 477-480.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hostetler et al., Effect of Cyclodextrin on the Pharmacology of Antifungal Oral Azoles , Antimicrobial Agents And Chemotherapy , Feb. 1992, pp. 477 480.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pitha et al., "<a href='http://scholar.google.com/scholar?q="Preparation+of+drug%3Ahydroxypropylcyclodextrin+complexes+by+a+method+using+ethanol+or+aqueous+ammonium+hydroxide+as+co-solubilizers"'>Preparation of drug:hydroxypropylcyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as co-solubilizers</a>", International Journal of Pharmaceutics, 80 (1992) 253-258.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Pitha et al., Preparation of drug:hydroxypropylcyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as co solubilizers , International Journal of Pharmaceutics , 80 (1992) 253 258.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6207703">US6207703</a></td><td class="patent-data-table-td patent-date-value">Oct 22, 1998</td><td class="patent-data-table-td patent-date-value">Mar 27, 2001</td><td class="patent-data-table-td ">Jens Ponikau</td><td class="patent-data-table-td ">Mucoadministering to airways formulation comprising antifungal agent to reduce or eliminate symptoms of asthma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6291500">US6291500</a></td><td class="patent-data-table-td patent-date-value">Oct 22, 1998</td><td class="patent-data-table-td patent-date-value">Sep 18, 2001</td><td class="patent-data-table-td ">Jens Ponikau</td><td class="patent-data-table-td ">Administering an antifungal agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6340698">US6340698</a></td><td class="patent-data-table-td patent-date-value">Nov 24, 2000</td><td class="patent-data-table-td patent-date-value">Jan 22, 2002</td><td class="patent-data-table-td ">Bernard Charles Sherman</td><td class="patent-data-table-td ">Pharmaceutical solution, substantially free of cyclodextrin, for oral administration comprising itraconazole or saperconazole, acid and one or more alcoholic cosolvents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6379707">US6379707</a></td><td class="patent-data-table-td patent-date-value">Jun 21, 2001</td><td class="patent-data-table-td patent-date-value">Apr 30, 2002</td><td class="patent-data-table-td ">Fmc Corporation</td><td class="patent-data-table-td ">Solid solution of amorphous pharmaceutically active agent, pharmaceutically acceptable hydrophobic vehicle, stabilizer, disintegrant; shelf life</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6497905">US6497905</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 2000</td><td class="patent-data-table-td patent-date-value">Dec 24, 2002</td><td class="patent-data-table-td ">R.P. Scherer Technologies, Inc.</td><td class="patent-data-table-td ">Aqueous solubility pharmaceutical formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6511681">US6511681</a></td><td class="patent-data-table-td patent-date-value">Jun 21, 2001</td><td class="patent-data-table-td patent-date-value">Jan 28, 2003</td><td class="patent-data-table-td ">R.P. Scherer Technologies, Inc.</td><td class="patent-data-table-td ">Solubility and bioavailability of azole antifungal medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6555566">US6555566</a></td><td class="patent-data-table-td patent-date-value">May 25, 2001</td><td class="patent-data-table-td patent-date-value">Apr 29, 2003</td><td class="patent-data-table-td ">Mayo Foundation For Medical Education And Research</td><td class="patent-data-table-td ">Methods and materials for treating and preventing inflammation of mucosal tissue</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6673373">US6673373</a></td><td class="patent-data-table-td patent-date-value">Apr 5, 2002</td><td class="patent-data-table-td patent-date-value">Jan 6, 2004</td><td class="patent-data-table-td ">Carlsbad Technology Inc.</td><td class="patent-data-table-td ">Antifungal formulation and the methods for manufacturing and using the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6806256">US6806256</a></td><td class="patent-data-table-td patent-date-value">Feb 26, 2002</td><td class="patent-data-table-td patent-date-value">Oct 19, 2004</td><td class="patent-data-table-td ">Ortho -Mcneil Pharmaceutical, Inc.</td><td class="patent-data-table-td ">Especially a bitter tasting antibiotic containing an artificial sweetener</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7078526">US7078526</a></td><td class="patent-data-table-td patent-date-value">May 30, 2003</td><td class="patent-data-table-td patent-date-value">Jul 18, 2006</td><td class="patent-data-table-td ">Transform Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Crystal structured fungicides selected from itraconazole, posaconazole or saperconazole used for prevention or prophylaxis of fungi, yeasts and dermatophyte infections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7446107">US7446107</a></td><td class="patent-data-table-td patent-date-value">Aug 26, 2004</td><td class="patent-data-table-td patent-date-value">Nov 4, 2008</td><td class="patent-data-table-td ">Transform Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Soluble crystalline form of cis-itraconazole, posaconazole or saperconazole comprising the reaction product of cis-itraconazole, posaconazole or saperconazole and an organic acid or an inorganic acid; use in treating or preventing local and systemic fungal, yeast, and dermatophyte infections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7790905">US7790905</a></td><td class="patent-data-table-td patent-date-value">Dec 29, 2003</td><td class="patent-data-table-td patent-date-value">Sep 7, 2010</td><td class="patent-data-table-td ">Mcneil-Ppc, Inc.</td><td class="patent-data-table-td ">sodium salt of celecoxib</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7927613">US7927613</a></td><td class="patent-data-table-td patent-date-value">Sep 11, 2003</td><td class="patent-data-table-td patent-date-value">Apr 19, 2011</td><td class="patent-data-table-td ">University Of South Florida</td><td class="patent-data-table-td ">Pharmaceutical co-crystal compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8183290">US8183290</a></td><td class="patent-data-table-td patent-date-value">Jul 20, 2010</td><td class="patent-data-table-td patent-date-value">May 22, 2012</td><td class="patent-data-table-td ">Mcneil-Ppc, Inc.</td><td class="patent-data-table-td ">Pharmaceutically acceptable propylene glycol solvate of naproxen</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8362062">US8362062</a></td><td class="patent-data-table-td patent-date-value">Dec 24, 2003</td><td class="patent-data-table-td patent-date-value">Jan 29, 2013</td><td class="patent-data-table-td ">Mcneil-Ppc, Inc.</td><td class="patent-data-table-td ">Pharmaceutical compositions with improved dissolution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8492423">US8492423</a></td><td class="patent-data-table-td patent-date-value">Apr 3, 2012</td><td class="patent-data-table-td patent-date-value">Jul 23, 2013</td><td class="patent-data-table-td ">Mcneil-Ppc, Inc.</td><td class="patent-data-table-td ">Pharmaceutical propylene glycol solvate compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1067897A1?cl=en">EP1067897A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 29, 1999</td><td class="patent-data-table-td patent-date-value">Jan 17, 2001</td><td class="patent-data-table-td ">Johnson &amp;amp; Johnson Consumer Companies, Inc.</td><td class="patent-data-table-td ">An acidified composition for topical treatment of nail and skin conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363113A1?cl=en">EP2363113A1</a></td><td class="patent-data-table-td patent-date-value">Dec 4, 2007</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Supernus Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Enhanced immediate release formulations of topiramate</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S058000">514/58</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S254070">514/254.07</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0031040000">A61P31/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047480000">A61K47/48</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009000000">A61K9/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047400000">A61K47/40</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0045080000">A61K45/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031410000">A61K31/41</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031495000">A61K31/495</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047100000">A61K47/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009080000">A61K9/08</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/48969">A61K47/48969</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/40">A61K47/40</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B82Y5/00">B82Y5/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/0095">A61K9/0095</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=srhEBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/495">A61K31/495</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">B82Y5/00</span>, <span class="nested-value">A61K9/00Z6</span>, <span class="nested-value">A61K31/495</span>, <span class="nested-value">A61K47/40</span>, <span class="nested-value">A61K47/48W18B</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Jun 10, 2009</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 24, 2007</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1, 6 AND 7 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 2-5, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 8 AND 9 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 28, 2006</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20051109</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 3, 2005</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 30, 2005</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 19, 2001</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 22, 1996</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">JANSSEN PHARMACEUTICA N.V., BELGIUM</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRANCOIS, MARC KAREL JOZEF;DRIES, WILLY MARIA ALBERT;REEL/FRAME:008026/0348</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19960201</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2fyByJkk1_S6GneE31QCqPQHQkxg\u0026id=srhEBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U3jnGgthvVw2DCSJG9kJfsCr4J5Ww\u0026id=srhEBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U0d6oe_o213Hr2lCOiykBU7QS5p9g","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Itraconazole_or_saperconazole_hydroxypro.pdf?id=srhEBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0zzV6y3CPENUmrdvu0X4RoEzeCFA"},"sample_url":"http://www.google.com/patents/reader?id=srhEBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>